| scholarly article | Q13442814 |
| P50 | author | Krister Wennerberg | Q31058683 |
| Tero Aittokallio | Q41044826 | ||
| P2093 | author name string | Johanna Magga | |
| Olli Tenhunen | |||
| Risto Kerkelä | |||
| Suleiman Khan | |||
| Manar Elmadani | |||
| P2860 | cites work | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 |
| PI3K/Akt/mTOR inhibitors in breast cancer | Q26771394 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale | Q28296128 | ||
| Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use | Q28541231 | ||
| Comprehensive analysis of kinase inhibitor selectivity | Q29616719 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Insulin Signaling and Heart Failure. | Q30377910 | ||
| Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies | Q30436867 | ||
| Cardiovascular side effects of small molecule therapies for cancer. | Q54167171 | ||
| Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. | Q54609364 | ||
| Glycolysis is predominant source of myocardial ATP production immediately after birth | Q67779182 | ||
| Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation | Q74027974 | ||
| Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes | Q79367416 | ||
| In vitro assays and techniques utilized in anticancer drug discovery | Q90730801 | ||
| Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling | Q33552565 | ||
| Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. | Q33997854 | ||
| Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes | Q34576324 | ||
| Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer | Q35072441 | ||
| Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis | Q35093122 | ||
| Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome | Q35224437 | ||
| A historical overview of protein kinases and their targeted small molecule inhibitors | Q35711076 | ||
| Drug-induced mitochondrial dysfunction and cardiotoxicity | Q36339445 | ||
| Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation | Q36924800 | ||
| Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib | Q37098098 | ||
| Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives | Q37132788 | ||
| Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem | Q37212411 | ||
| Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death | Q37362206 | ||
| Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. | Q37833892 | ||
| Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome | Q38041992 | ||
| Cancer genetics and the cardiotoxicity of the therapeutics. | Q38074793 | ||
| Oncocardiology-Past, Present, and Future: A Review | Q38829737 | ||
| Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue | Q38850598 | ||
| Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies | Q38863833 | ||
| Cardiac mTOR complex 2 preserves ventricular function in pressure-overload hypertrophy | Q40284379 | ||
| The role of PI3Kα isoform in cardioprotection | Q42683501 | ||
| The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro | Q42910592 | ||
| Inhibition of the PI3K pathway: hope we can believe in? | Q43094929 | ||
| The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity | Q43203234 | ||
| Calcium signaling mechanisms in dedifferentiated cardiac myocytes: comparison with neonatal and adult cardiomyocytes. | Q43811952 | ||
| The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. | Q45949164 | ||
| The RISK pathway and beyond. | Q47100578 | ||
| Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions | Q47252031 | ||
| The target landscape of clinical kinase drugs | Q47345032 | ||
| New Insights Into the Role of mTOR Signaling in the Cardiovascular System. | Q48506350 | ||
| Kinase-targeted cancer therapies: progress, challenges and future directions | Q49887882 | ||
| Cardiomyocyte Proliferation: Teaching an Old Dogma New Tricks | Q50455506 | ||
| P433 | issue | 21 | |
| P304 | page(s) | e013018 | |
| P577 | publication date | 2019-10-16 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival | |
| P478 | volume | 8 |
Search more.